Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 13/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.51 |
| ▸ | RPS6KA2 | Q15349 | 6/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17361128 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123496 | 1.00 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361078 | 0.98 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123204 | 0.98 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361094 | 0.98 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123421 | 0.87 | MAPKAPK2 (0.52) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361165 | 0.87 | MAPKAPK2 (0.65) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123205 | 0.87 | MAPKAPK2 (0.65) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361136 | 0.87 | MAPKAPK2 (0.65) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361115 | 0.87 | MAPKAPK2 (0.52) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.